## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# CTATEMENT OF CHANCES IN DENERICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Ellias F					2. Issuer Name and Ticker or Trading Symbol SAB Biotherapeutics, Inc. [ SABS ]  3. Date of Earliest Transaction (Month/Day/Year) 11/01/2024						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)    Director 10% Owner Officer (give title below) Other (specify below)				
777 W 41ST STREET, SUITE 401  (Street)  MIAMI BEACH FL 33140  (City) (State) (Zip)  Table I - Non-Deriva					4. If Amendment, Date of Original Filed (Month/Day/Year)  ative Securities Acquired, Disposed of, or Benefic						Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person  Cially Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,		Code (Ins	on Dispostr. 5)	A. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4:5)  Amount (A) or Price		5. Amount of Securities F Beneficially (I		. Ownership form: Direct D) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		(e.g., puts, ca		5. Number of		, ,		ed of, or Benefic nvertible securit e and 7. Title and At of Securities Underlying Derivative Sec (Instr. 3 and 4		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiratio Date	n Title	Amount or Number of Shares					
Stock Option (right to buy) <sup>(1)(3)</sup>	\$3.88	11/01/2024		A		20,000		(1)	11/01/203	4 Common Stock	20,000	\$0	20,000	D		
Stock Option (right to buy) <sup>(2)(3)</sup>	\$3.88	11/01/2024		A		35,000		(2)	11/01/203	4 Common Stock	35,000	\$0	35,000	D		

#### Explanation of Responses:

- 1. Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on November 1, 2025, and 2026.
- 2. Represents the inaugural grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on November 1, 2025, 2026, and 2027.
- 3. This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

/s/ Katie Ellias

11/05/2024

ctly.

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.